您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > LH 21
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LH 21
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LH 21图片
CAS NO:611207-11-5
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
LH-21 是一种有效的体内中性大麻素 CB1 受体拮抗剂。
Cas No.611207-11-5
化学名5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole
Canonical SMILESCCCCCCC1=NN(C2=CC=C(Cl)C=C2Cl)C(C3=CC=C(Cl)C=C3)=N1
分子式C20H20Cl3N3
分子量407.1
溶解度≤10mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 631 ±98 and 690 ± 41 nM for human and rat CB1 receptors, respectively

LH 21 is a CB1 antagonist.

The endogenous cannabinoid system plays a critical modulatory role in feeding behavior and metabolism, acting at both peripheral and central levels. Recently studies suggest that the chronic administration of cannabinoid CB1 receptor antagonists is effective in experimental obesity.

In vitro: Previous study showed that LH-21 was able to inhibit the binding of [3H]CP55940 to cloned human and rat CB1 receptors with IC50 values of 631 ±98 nM, and 690 ± 41 nM, respectively. LH-21 acted as an inverse agonist in a cAMP functional assay using cultured cells expressing human, rat or mouse CB1 receptor. In addition, in CHO cells overexpressing CB1, LH-21 was able to elevate cAMP, further confirming that LH-21 acted as an inverse agonist of CB1 in this model [1].

In vivo: Animal study showed that when given acutely LH-21 could decrease food intake and enhance the anorectic actions of oleoylethanolamide, a feeding suppressant lipid acting on peripheral sensory terminals in a similar way as rimonabant. However, unlike rimonabant, chronic administration of LH-21 at 3 mg/kg was able to reduce feeding but did not improve hypercholesterolaemia or hypertriglyceridaemia; nor did it reduce liver fat deposits in Zucker rats [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Chen, R. Z.,Frassetto, A.,Lao, J.Z., et al. Pharmacological evaluation of LH-12, a newly discovered molecule that binds to cannabinoid CB1 receptor. European Journal of Pharmacology 584, 338-342 (2008).
[2] Pavón, F. J.,Serrano, A.,Pérez-Valero, V., et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Journal of Neuroendocrinology 20, 116-123 (2008).